Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis
Last updated Oct 27, 2026
Health Check
Last analyzed Oct 23, 2026
- Financial Health 50
- Profitability 75
- Business Quality 60
- Balance Sheet 40
- Cash Flow 45
Why this rating?
Health 56/100 — Acceptable
Entry timing is weak right now. Quality may be fine; the setup is not.
Company overview
Amneal Pharmaceuticals, Inc. (AMRX) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector. Compound Radar rates Amneal Pharmaceuticals, Inc. 56/100 (Acceptable) due to solid business quality, steady revenue growth, and elevated leverage.
Investment profile
- Quality Moderate
- Growth Moderate
- Balance Sheet Stretched
- Valuation Attractive
Financial highlights
Valuation
- P/E 43.76
- Forward P/E 17.81
- PEG 2
- EV/Revenue 3.08
Profitability
- Revenue Growth 9.9%
- Gross Margin 39.8%
- Operating Margin 18.3%
- Net Margin 5.0%
- ROE 613.0%
Financial strength
- Cash $131.41M
- Debt $2.79B
- Net Cash $-2.66B
- Free Cash Flow $225.63M
- Current Ratio 2.21
Similar companies
Peers in Drug Manufacturers - Specialty & Generic, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- United Therapeutics Corporation Drug Manufacturers - Specialty & Generic UTHR$591.20 78 Health 78 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- BioCryst Pharmaceuticals, Inc. Drug Manufacturers - Specialty & Generic BCRX$8.10 78 Health 78 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Strong Entry Strong EntryTiming looks favorable across trend, momentum, valuation, support, and catalysts.
- Zoetis Inc. Drug Manufacturers - Specialty & Generic ZTS$78.23 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Neurocrine Biosciences, Inc. Drug Manufacturers - Specialty & Generic NBIX$146.00 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Strong Entry Strong EntryTiming looks favorable across trend, momentum, valuation, support, and catalysts.
- Lantheus Holdings, Inc. Drug Manufacturers - Specialty & Generic LNTH$100.15 70 Health 70 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Trulieve Cannabis Corp. Drug Manufacturers - Specialty & Generic TRLV$10.67 64 Health 64 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Alkermes plc Drug Manufacturers - Specialty & Generic ALKS$44.32 62 Health 62 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Hims & Hers Health, Inc. Drug Manufacturers - Specialty & Generic HIMS$27.92 61 Health 61 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
FAQ
How Compound Radar scores and tracks Amneal Pharmaceuticals, Inc. (AMRX).